

Is Detrusor Overactivity a predictor factor of Posterior Tibial Nerve Stimulation outcome in the treatment of Overactive

Bladder?

Waleed Alamrai, Basma Malalla, Ali Alabbad, Magdi Algahwari, Mohammed Aldokhi, Osama Sarhan, and Riyad Al Mousa¹. King Fahad Specialist Hospital - Dammam, Saudi Arabia



ePoster 640

Introduction and aim of Study

*Posterior Tibial Nerve Stimulation (PTNS) is a well-known treatment option for overactive bladder (OAB) not responding to conventional treatment 1-3.

*Herein, our aim is to assess the significance of Urodynamic proven Detrusor Overactivity (DO) on the outcome of PTNS in patients with OAB syndrome.



Methods and Materials

•Single center, retrospective study, reviewed the medical charts of all adult patients with OAB with or without detrusor Overactivity (DO) who underwent Posterior Tibial Nerve Stimulation (PTNS) between January 2012 until December 2018.

•Hospital Institutional review board was obtained before starting the study. Patients' demographic data, diagnosis, voiding diary pre and post Posterior Tibial Nerve Stimulation (PTNS) treatment, and outcome collected. All patients had baseline investigations (urine analysis, serum Creatinine, Urodynamic study, Renal Ultrasound).

•Each Patient had to fill a voiding diary and quality of life questionnaire at the beginning of therapy (Week 0) and after completion of the initial weekly therapy (week 12). 4

•The success of treatment was defined as 50% or more improvement of voiding dysfunction symptoms in voiding diary. ⁵

•PTNS was continued for 24 sessions in patients who showed 50% improvement or more of symptoms after 12 sessions. Patients who were considered as success completed another twice/month sessions for three months then once/month sessions for another 6 months (total of 12 Months therapy). 5

Results

•Forty-nine patients (35 female and 14 male) with a mean age of 43 years (range 18-77) were included. Two patients were excluded from the study because no urodynamic study was done.

•Twenty-nine patients (59.2%) had no DO and 20 patients (40.8%) had DO. •PTNS treatment showed an overall success rate of 61.5%.

•In OAB patients with no DO, 15 patients (51.7%) had improvement, while 16 OAB patients with DO (80%) had Improvement.

•There is a statistical significant difference between the outcomes in both groups (p < 0.05).




Fig.2 Results according to presence of DO or not






Fig.3:UDS findings

Discussion

All patients have completed all sessions with no complications or significant side effects. Results showed that patients with proven detrusor Over activity by Urodynamic study have a statistically significant outcome over those who has urgency frequency syndrome without Urodynamic proven Over activity.

Conclusions

•In patients with OAB, an urodynamic proven Detrusor Over activity (DO) predicts posterior Tibial Nerve Stimulation outcome.

•Success rate is more frequently encountered after PTNS treatment in patients in whom urodynamic evaluation showed DO compared to those with negative DO on urodynamic (Urgency frequency syndrome).




Fig.1: PTNS overall success.

Disclosure

•Nothing to disclose.

Contact

•Dr.Riyad Al Mousa

riyad100@Hotmail.com

References

- 1.McGuire EJ, Zhang SC, Horwinski ER et al: Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol 1983; 129: 78.
- 2. Stoller ML: Afferent nerve stimulation for pelvic floor dysfunction. Eur Urol 1999; 35: 16.
- 3. Peters K, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. *J Urol*. 2009;182:1055–1061.
- 4.Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–1198
- 5.MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010;183:234–240